Skip to content
MedsAcross

Medicine

Tacrolimus 0.1% ointment

Tacrolimus · Topical
Available on requestPrescription onlyUS FDAGeneric name

Tacrolimus 0.1% ointment is a generic prescription medicine for topical use, made by 5 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 25°C (77°F): excursions permitted to 15°C to 30°C (59°F to 86°F)…

Key facts

Active ingredient (INN)
Tacrolimus
Brand
Sold under the generic name
Strength
0.1%
Dosage form
Ointment
Route
Topical
Packs
1 tube and 12 more
Manufacturers
Accord HealthcareIndiaGlenmark PharmaceuticalsIndiaE. FougeraEncube EthicalsPadagis Israel Pharmaceuticals
Origin register
US FDA, United States
Storage
Store at 25°C (77°F): excursions permitted to 15°C to 30°C (59°F to 86°F) Manufactured for: Accord Healthcare, Inc., 8041 Arco Corporate Drive, Suite 200, Raleigh, NC 27617, USA.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
D11AH01 Tacrolimus
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
9 September 2014
Identifiers
RxCUI 313189, 314266DailyMed set ID 80e6817a-9b1e-4f0f-e053-2a91aa0a3d15, 43b38551-6c5e-48a4-a453-9286f1c16b34, 6b601eaf-4f3a-4a8b-8cd8-1000defa9822 +2NDC 16729-422, 21922-011, 45802-700 +2Application ANDA211688, ANDA212387, NDA050777 +2

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

Packs from every labeler of this generic presentation.

PackCodeLabelerMarketed since
1 tube in 1 carton / 100 g in 1 tube16729-422-01Accord HealthcareIndia5 June 2019
1 tube in 1 carton / 30 g in 1 tube16729-422-10Accord HealthcareIndia31 May 2019
1 tube in 1 carton / 60 g in 1 tube16729-422-12Accord HealthcareIndia31 May 2019
1 tube in 1 carton / 30 g in 1 tube68462-534-35Glenmark PharmaceuticalsIndia16 April 2018
1 tube in 1 carton / 60 g in 1 tube68462-534-65Glenmark PharmaceuticalsIndia16 April 2018
1 tube in 1 carton / 100 g in 1 tube68462-534-94Glenmark PharmaceuticalsIndia16 April 2018
1 tube in 1 carton / 30 g in 1 tube0168-0416-30E. Fougera9 September 2014
1 tube in 1 carton / 60 g in 1 tube0168-0416-60E. Fougera9 September 2014
1 tube in 1 carton / 100 g in 1 tube0168-0416-99E. Fougera9 September 2014
1 tube in 1 carton / 30 g in 1 tube21922-011-05Encube Ethicals13 October 2023
1 tube in 1 carton / 60 g in 1 tube21922-011-07Encube Ethicals13 October 2023
1 tube in 1 carton / 100 g in 1 tube21922-011-09Encube Ethicals13 October 2023
1 tube in 1 carton / 30 g in 1 tube45802-700-00Padagis Israel Pharmaceuticals20 November 2014
1 tube in 1 carton / 60 g in 1 tube45802-700-01Padagis Israel Pharmaceuticals20 November 2014
1 tube in 1 carton / 100 g in 1 tube45802-700-02Padagis Israel Pharmaceuticals20 November 2014

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 8 April 1994Drugs@FDA
EU (EMA)AuthorisedEMA medicines data
India (CDSCO)Not yet confirmed against CDSCO approval lists—
AustriaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BelgiumRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BulgariaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CroatiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CyprusRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CzechiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
DenmarkRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
EstoniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FinlandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FranceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GermanyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GreeceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
HungaryRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IcelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IrelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
ItalyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LatviaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LiechtensteinRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LithuaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LuxembourgRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
MaltaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NetherlandsRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NorwayRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PolandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PortugalRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
RomaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SlovakiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SloveniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SpainRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SwedenRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Other strengths and forms of Tacrolimus

Clinical summary

Tacrolimus is a calcineurin inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants. MedsAcross supplies Tacrolimus for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Tacrolimus

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Tacrolimus 0.1% ointment for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.